Nuviant Medical Announces Engagement Of Investment Banking Firm Healthios Capital Markets, LLC To Provide Strategic Advisory Services

DALLAS, July 28, 2015 /PRNewswire-iReach/ -- Nuviant Medical ("Nuviant" or "the Company"), a medical device developer and manufacturer, announced today that it has retained Healthios Capital Markets, LLC ("Healthios"), a premiere investment bank primarily focused on the global healthcare industry, to provide strategic corporate planning and investment banking services.  Healthios will be dedicated to optimizing shareholder value through its broad scope banking services.

"[Nuviant] is excited to have partnered with a bank that has expertise in the field of healthcare and a history of getting deals done in this space," said Nuviant CEO Will Rosellini. "Healthios' proven track record gives us confidence that they will help guide us along a path that maximizes benefits to our shareholders."

"Nuviant is a solid addition to our client portfolio as it boasts all of the components needed in a successful company, and it has already demonstrated tremendous progress in its short lifetime," stated Greg Shearer, Managing Director of Healthios. "Their strong and experienced management team has generated substantial value with a fraction of the capital required for most companies.  With manufacturing capabilities and a healthy IP portfolio, they are attacking markets with large opportunity.  We look forward to supporting their future efforts via strategic planning, advising on potential acquisitions, and introducing the company to the investment community."

About Nuviant Medical - Nuviant Medical, formerly known as nUro, Inc., arose from viable clinical programs developed internally and acquired from Medtronic. These programs were initiated at Rosellini Scientific via support from the National Institutes of Health (NIH) SBIR program.  The formation of the company was finalized with the acquisition of Synaptix, a vertically integrated medical device manufacturing company with a CE Marked deep brain stimulator. This 16-channel recording and stimulation platform (SynapseTM) has been deployed in clinical studies for the treatment of movement disorders. In addition, the Company developed a wireless version of the device for use in the peripheral nervous system, most notably for the treatment of incontinence-related disorders. Nuviant Medical has now produced and tested its device conforming to Good Manufacturing Practice (GMP) in its class 10,000 clean-room.  For more information on Nuviant Medical, please visit our website at www.nuviantmedical.com

Forward-Looking Statements:  This news release contains forward-looking statements which may be identified by their use of words like "plans," "expects," "will," "believes," "intends," "estimates," "anticipates" or other words of similar meaning.  All statements that address expectations or projections about the future, including statements about the company's growth strategy, product development, regulatory approval, market position, anticipated benefits of acquisitions, timing of anticipated benefits from restructuring actions, outcome of contingencies, such as litigation and environmental matters, expenditures and financial results, are forward-looking statements.  Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized.  Forward-looking statements also involve risks and uncertainties, many of which are beyond the company's control.  Some of the important factors that could cause the company's actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; significant litigation and environmental matters; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, weather events and natural disasters; ability to protect and enforce the company's intellectual property rights; successful integration of acquired businesses and separation of under-performing or non-strategic assets or businesses. The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.

Photo - http://photos.prnewswire.com/prnh/20150727/246010

Media Contact:Beth Rosellini, Nuviant Medical, Inc., 1-888-907-6876, beth@nuviantmedical.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Nuviant Medical, Inc